Related Experiment Video
Updated: Oct 11, 2025

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target
Gergely Rona1,2,3, Andras Zeke1,2,4, Bearach Miwatani-Minter1,2
1Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Abstract:
The risk of zoonotic coronavirus spillover into the human population, as highlighted by the SARS-CoV-2 pandemic, demands the development of pan-coronavirus antivirals. The efficacy of existing antiviral ribonucleoside/ribonucleotide analogs, such as remdesivir, is decreased by the viral proofreading exonuclease NSP14-NSP10 complex. Here, using a novel assay and in silico modeling and screening, we identified NSP14-NSP10 inhibitors that increase remdesivir's potency. A model compound, sofalcone, both inhibits the exonuclease activity of SARS-CoV-2, SARS-CoV, and MERS-CoV in vitro, and synergistically enhances the antiviral effect of remdesivir, suppressing the replication of SARS-CoV-2 and the related human coronavirus OC43. The validation of top hits from our primary screenings using cellular systems provides proof-of-concept for the NSP14 complex as a therapeutic target.
Insights
Developing pan-coronavirus antivirals is crucial. Researchers identified compounds inhibiting the NSP14-NSP10 complex, enhancing remdesivir
Area of Science:
- Virology
- Drug Discovery
- Molecular Biology
Background:
- The COVID-19 pandemic underscores the threat of zoonotic coronaviruses.
- Existing antivirals like remdesivir are hindered by viral proofreading mechanisms.
Purpose of the Study:
- To identify inhibitors of the SARS-CoV-2 NSP14-NSP10 complex.
- To enhance the efficacy of existing antiviral therapies.
Main Methods:
- Development of a novel assay for screening.
- In silico modeling and virtual screening.
- In vitro inhibition assays and cellular replication studies.
Main Results:
- Identified inhibitors of the NSP14-NSP10 exonuclease complex.
- Sofalcone demonstrated inhibition of SARS-CoV-2, SARS-CoV, and MERS-CoV exonuclease activity.
- Sofalcone synergistically enhanced remdesivir's antiviral effect and suppressed viral replication.
Conclusions:
- The NSP14-NSP10 complex is a viable therapeutic target for pan-coronavirus drug development.
- Inhibiting viral proofreading mechanisms can restore antiviral potency.
- This approach offers a strategy for developing broad-spectrum coronavirus therapeutics.
Related Concept Videos
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Viruses with RNA Genomes
Leaky Scanning

